A reverse phase stability indicating HPLC method for simultaneous determination of two antispasmodic drugs in pharmaceutical parenteral dosage forms (injectable) and in serum has been developed and validated. Mobile phase ingredients consist of Acetonitrile:buffer:sulfuric acid 0.1M (50:50:0.3 v/v/v), at flow rate 1.0mL/min using a Hibar μBondapak ODS C18 column monitored at dual wavelength of 266nm and 205nm for phloroglucinol and trimethylphloroglucinol, respectively. The drugs were subjected to stress conditions of hydrolysis (oxidation, base, acid, and thermal degradation). Oxidation degraded the molecule drastically while there was not so much significant effect of other stress conditions. The calibration curve was linear with a correlation coefficient of 0.9999 and 0.9992 for PG and TMP, respectively. The drug recoveries fall in the range of 98.56% and 101.24% with 10pg/mL and 33pg/mL limit of detection and limit of quantification for both phloroglucinol and trimethylphloroglucinol. The method was validated in accordance with ICH guidelines and was applied successfully to quantify the amount of trimethylphloroglucinol and phloroglucinol in bulk, injectable form and physiological fluid. Forced degradation studies proved the stability indicating abilities of the method.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, rapidly progressive malignancy-related pulmonary vascular condition that remains difficult to diagnose before death due to its nonspecific clinical and imaging features. Recent advances in metabolomics, particularly when powered by artificial intelligence (AI), offer promising opportunities for early detection by identifying distinct metabolic signatures. While AI-driven metabolomics has shown success in various cancers, its application to PTTM is challenged by the rarity of the disease, limited datasets, and privacy concerns. Innovations such as multicenter collaborations and blockchain-based data sharing may help overcome these barriers. Integrating AI and metabolomics has the potential to revolutionize not only the diagnosis of PTTM but also other rare diseases with elusive early biomarkers.